MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Interest Expense 2011-2026 | NVTA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.7 M | 49.9 M | 29.8 M | 12.4 M | 7.03 M | 3.65 M | 421 K | 211 K | 61 K | 59 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.7 M | 59 K | 16 M |
Quarterly Interest Expense Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.85 M | 6.02 M | 11.5 M | - | 14.1 M | 14 M | 14 M | - | 14.1 M | 13.4 M | 8.39 M | - | 6.31 M | 5.48 M | 5.45 M | - | 2.83 M | 2.12 M | 2.11 M | - | 1.84 M | 1.79 M | 1.29 M | - | 1.13 M | 1.07 M | 322 K | - | 115 K | 100 K | 84 K | - | 62 K | 35 K | 28 K | - | 15 K | 17 K | 17 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 M | 15 K | 4.45 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
-1.45 M | $ 9.0 | 1.47 % | $ 600 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 26.24 | 1.59 % | $ 729 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 154.17 | 1.45 % | $ 7.64 B | USA |
 |
DexCom
DXCM
|
177 M | $ 68.54 | 3.32 % | $ 26.7 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.77 | 2.6 % | $ 947 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 88.16 | 1.12 % | $ 11.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.95 | 0.1 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.57 | 4.15 % | $ 471 M | USA |
|
Biodesix
BDSX
|
8.26 M | $ 17.22 | -0.4 % | $ 2.23 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 101.08 | 3.55 % | $ 8.34 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.88 | 1.23 % | $ 93.5 K | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 169.85 | 3.01 % | $ 29.2 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 195.65 | 2.23 % | $ 139 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 121.72 | 2.04 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 198.39 | -0.28 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
81 M | $ 113.9 | 1.85 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.12 | 0.91 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 9.28 | 10.24 % | $ 263 M |  Israel |
 |
NeoGenomics
NEO
|
296 K | $ 8.39 | 1.76 % | $ 1.07 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.45 | 3.73 % | $ 2.05 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 78.83 | 0.41 % | $ 5.32 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.41 | 3.68 % | $ 423 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 458.61 | 1.1 % | $ 13.2 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 220.43 | 1.77 % | $ 25.2 B |  Schweiz |
 |
Celcuity
CELC
|
2.11 M | $ 115.07 | 0.15 % | $ 4.54 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 18.31 | 5.23 % | $ 410 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
9.32 M | $ 201.15 | 1.76 % | $ 19.8 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.2 | 0.84 % | $ 833 M | USA |